EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pathology Findings and In-Life Correlates in the Nonclinical Development of Adeno-Associated Virus (AAV)-Based Retinal Gene Therapies

Helen S Booler iD, Typhaine Lejeune, Oliver Turner iD, Chandra Saravanan iD, Joshua T Bartoe, Brad Bolon iD

Toxicologic Pathology · 2024-12 · 52 (8) · 506-522

DOI: 10.1177/01926233241307641 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 26.12.2024. Verfasst von Helen S Booler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Novartis, Basel, Switzerland. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adeno-associated virus (AAV)-based vectors are the most frequently used platform for retinal gene therapy. Initially explored for the treatment of loss-of-function mutations underpinning many inherited retinal diseases, AAV-based ocular gene therapies are increasingly used to transduce endogenous cells to produce therapeutic proteins, thus producing site-specific biofactories. Relatively invasive ocular routes of administration (ROA) mean prominent procedure-related in-life, and histopathological findings may be observed with some regularity. Test article-related findings may vary with the ROA and cell populations transduced, with retinal pigmented epithelium (RPE) changes prominent (ranging from pigment alteration through degeneration, with or without associated degeneration of the overlying retina) with subretinal ROA, and more anterior changes (iris, ciliary body) generally observed with the intravitreal ROA. Ocular inflammation is the most frequent finding that occurs nonclinically and in patients, and is particularly pronounced with intravitreal administration. Extraocular findings may be observed in extraocular muscles, regional ganglia, or central visual pathways with multiple ocular ROA. Work is still needed to understand the mechanisms underpinning many of these ocular and extraocular findings. Emerging patient data is helping to clarify both the potential for translating nonclinical findings to predict possible human responses and the applicability of nonclinical biomonitoring methods to the clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGenetic TherapyGenetic VectorsAnimalsHumansRetinal DiseasesRetinaRetinal Pigment Epithelium

Stichwörter der Autor:innen

AAVeyegene therapynonhuman primateocular toxicityretinasafety testing

Autor:innen und Institutionen

  • Novartis, Basel, Switzerland.
  • Charles River Laboratories Montreal ULC, Senneville, Quebec, Canada.
  • Novartis, East Hanover, New Jersey, USA.
  • Novartis, Cambridge, Massachusetts, USA.
  • Northern Biomedical Research, Norton Shores, Michigan, USA.
  • GEMpath, Inc., Longmont, Colorado, USA.

ORCID-Profile: Helen S Booler, Oliver Turner, Chandra Saravanan, Brad Bolon

Zitieren

APA

Booler, H. S., Lejeune, T., Turner, O., Saravanan, C., Bartoe, J. T., & Bolon, B. (2024). Pathology Findings and In-Life Correlates in the Nonclinical Development of Adeno-Associated Virus (AAV)-Based Retinal Gene Therapies. Toxicologic Pathology, 52(8), 506-522. https://doi.org/10.1177/01926233241307641

Vancouver

Booler HS, Lejeune T, Turner O, Saravanan C, Bartoe JT, Bolon B. Pathology Findings and In-Life Correlates in the Nonclinical Development of Adeno-Associated Virus (AAV)-Based Retinal Gene Therapies. Toxicologic Pathology. 2024;52(8):506-522. doi:10.1177/01926233241307641

BibTeX
@article{Booler2024,
  author = {Booler, Helen S and Lejeune, Typhaine and Turner, Oliver and Saravanan, Chandra and Bartoe, Joshua T and Bolon, Brad},
  title = {Pathology Findings and In-Life Correlates in the Nonclinical Development of Adeno-Associated Virus (AAV)-Based Retinal Gene Therapies},
  journal = {Toxicologic Pathology},
  year = {2024},
  volume = {52},
  number = {8},
  pages = {506--522},
  doi = {10.1177/01926233241307641}
}
Kostenlos starten →